PYXS Stock Forecast: Pyxis Oncology, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Pyxis Oncology, Inc. is $7. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 74 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Pyxis Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (88): Sales and profits are climbing, and climbing faster than before.
Quality (32): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
PYXS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on PYXS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 4 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 6 Nov 2026 | RBC Capital | Maintains | Outperform | $6.00 → $7.00 |
| 6 Nov 2026 | Wedbush | Maintains | Outperform | $8.00 → $7.00 |
| 10 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $7.00 → $8.00 |
| 10 Sept 2026 | Wedbush | Maintains | Outperform | $6.00 → $8.00 |
| 9 Sept 2026 | RBC Capital | Maintains | Outperform | — |
| 9 Sept 2026 | Wells Fargo | Maintains | Overweight | $12 → $19 |
| 18 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $7.00 |
| 3 Aug 2026 | Wells Fargo | Initiates | Overweight | $12 |
| 2 July 2026 | Leerink Partners | Maintains | Outperform | $9.00 → $7.00 |
| 5 May 2026 | Wedbush | Initiates | Outperform | — |
| 24 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Mar 2026 | Stifel | Maintains | Buy | — |
| 19 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 19 Dec 2025 | RBC Capital | Maintains | Outperform | — |
| 24 Nov 2025 | Stephens & Co. | Maintains | Overweight | — |
| 4 Nov 2025 | Guggenheim | Maintains | Buy | — |
| 4 Sept 2025 | Guggenheim | Initiates | Buy | — |
| 19 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Mar 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for PYXS.
This page is one stock. Monday covers all of them.
PYXS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
PYXS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Pyxis Oncology, Inc. returned −60.3% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
PYXS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 19.6×
- Price / book
- 3.7×
- EV / EBITDA
- —
Cheaper than 8% of US stocks
Cheaper than 26% of US stocks
- Revenue growth (YoY)
- −100.0%
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
Higher than 1% of US stocks
- Return on equity
- −157.5%
- Return on assets
- −59.9%
- Dividend yield
- —
Higher than 9% of US stocks
Higher than 6% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Pyxis Oncology, Inc. has a market value of $216.5M and an enterprise value of $178.3M.
Revenue in the twelve months to 30 June 2026: $11.0M. The latest quarter shrank 100.0% year on year.
Net income over the same four quarters: −$88.7M, a −803.8% net margin.
Free cash flow in the twelve months to 30 June 2026: −$67.9M.
Pyxis Oncology, Inc. employs 56 people — $197K of revenue per employee.
Data provided by Twelve Data
PYXS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at PYXS’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Pyxis Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about PYXS
What is the PYXS stock price forecast for 2026-2027?
The median 12-month analyst price target for Pyxis Oncology, Inc. is $7, with estimates ranging from $5 to $19. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is PYXS stock a buy right now?
Of the 9 analysts covering Pyxis Oncology, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Pyxis Oncology, Inc. 74 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank PYXS?
As at 21 Nov 2026, Pyxis Oncology, Inc. ranks 74 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (88 of 100).
Will PYXS stock go up?
No one can know that. What the data says: the median 12-month target from 9 analysts is $7, and Ticker Nerd's factor model ranks Pyxis Oncology, Inc. 74 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the PYXS stock forecast for 2030?
No analyst covering Pyxis Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PYXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $19 over the next 12 months.
How has PYXS stock performed over the past year?
Pyxis Oncology, Inc. returned -60.3% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Pyxis Oncology, Inc. do?
Pyxis Oncology, Inc. Common Stock represents the equity of Pyxis Oncology, a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, with an emphasis on solid tumors. The company’s current pipeline centers on antibody-drug conjugates and immuno-oncology programs designed to directly attack tumor cells and help overcome immune suppression in cancer.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc. Common Stock represents the equity of Pyxis Oncology, a clinical-stage biopharmaceutical company focused on developing therapies for difficult-to-treat cancers, with an emphasis on solid tumors. The company’s current pipeline centers on antibody-drug conjugates and immuno-oncology programs designed to directly attack tumor cells and help overcome immune suppression in cancer. Its lead programs include micvotabart pelidotin, an investigational antibody-drug conjugate, along with additional candidates such as PYX-106 and PYX-107 that explore different mechanisms for targeting advanced cancers. Pyxis Oncology works across oncology research, clinical development, and translational medicine to advance product candidates intended for patients with limited treatment options. Headquartered in Boston, Massachusetts, Pyxis Oncology operates as part of the biotechnology sector and contributes to the broader development of precision cancer therapeutics.
CEO Mr. Thomas Civik · 56 employees · United States · https://www.pyxisoncology.com